Equity Profile

BEAM

Beam Therapeutics Inc.

Health CareBiotechnology$3.2B

May7Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market7:00 AM EDT

Beam Therapeutics Inc. Misses on EPS, Stock Down 2.69%

Metric	Actual	Expected	Surprise
EPS	$-0.91	N/A	-4.60%
Revenue	—	N/A	—

management commentary, guidance changes, and full analysis available with Pro.

Beam Therapeutics Inc. Misses on EPS, Stock Down 2.69%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-0.91	N/A	-4.60%
Revenue	—	N/A	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Beam Therapeutics reported a loss per share that was slightly worse than expected, contributing to a 2.69% decline in stock price. The lack of revenue figures and guidance leaves investors with limited insight into the company's future performance. Overall, the results indicate challenges that may affect investor confidence moving forward.

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for demonstrating the company's market traction and product demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology. This innovative approach aims to treat genetic diseases by directly correcting mutations at the DNA level, which could have significant implications for patient care in the health care sector.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

In the last quarter, Beam Therapeutics surprised analysts with a positive EPS of $2.33, significantly exceeding expectations. However, revenue figures were not disclosed, leaving some uncertainty about overall financial performance.

Management Promises & Guidance

Continued focus on advancing clinical trials for its lead product candidates.
Commitment to enhancing its base editing technology.
Plans to provide more detailed financial guidance in future reports.

Expectations

Wall Street Expectations

Overall expectations for Beam Therapeutics are mixed, with investors looking for clarity on future growth and clinical trial outcomes. The recent strong EPS surprise may lead to optimism, but uncertainty remains due to the lack of revenue guidance.

Bull Case

If Beam can demonstrate significant progress in its clinical trials and maintain strong EPS performance, it could attract more investors and drive the stock price higher.

Bear Case

Conversely, if the company fails to provide clear guidance on revenue or clinical trial results, it may lead to a sell-off, particularly given the recent volatility in its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and expected timelines for results?

The market will closely watch for updates on clinical trials, as these results can significantly impact the company's future prospects and stock price.

Will the company provide any revenue guidance or projections for the upcoming quarters?

Clear revenue guidance is essential for investor confidence, and any lack of clarity could lead to increased volatility in the stock.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Beam's clinical trial results, which could lead to significant upside if positive.

Supporting Evidence

The recent EPS surprise indicates that the company may be performing better than analysts expect.

Options pricing suggests that traders anticipate a larger move than historical averages, indicating potential for volatility.

The lack of revenue guidance may lead to overly cautious sentiment that doesn't reflect the company's actual progress.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment and challenge current bearish views.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to communicate progress in its clinical trials and provide financial clarity.

Bull Confirmed If

Demonstrating a clear path to commercialization for its lead product candidates, with positive clinical trial results.

Bear Confirmed If

Failure to provide any revenue guidance or disappointing updates on clinical trials.

Pre-Earnings Positioning

Options Market

Implied Move

±10.82%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±10.8% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

75.7%

Calls (30K)P/C Ratio: 0.23Puts (40K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +1.45%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack clarity, the stock may experience a muted reaction, reflecting investor caution.

Miss

If the company misses expectations, history suggests a potentially negative reaction, with an average 1-day move of -9.11%, indicating bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress and results of clinical trials for lead product candidates.
2Any commentary on revenue projections or financial guidance for the upcoming quarters.
3Insights into the competitive landscape and how Beam's technology compares.
4Management's perspective on the regulatory environment and potential hurdles.
5Plans for future product development and pipeline expansion.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

AXSMReported

Axsome Therapeutics, Inc.

RecapView

May4

KRYSReported

Company Snapshot

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines using its proprietary base editing technology....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

While specific revenue estimates are not available, growth in revenue is crucial for demonstrating the company's market traction and product demand.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+35.03%

Avg Stock Reaction

-2.71%

Last Quarter Recap

Management Promises & Guidance

Continued focus on advancing clinical trials for its lead product candidates.
Commitment to enhancing its base editing technology.
Plans to provide more detailed financial guidance in future reports.

Expectations

Wall Street Expectations

Bull Case

If Beam can demonstrate significant progress in its clinical trials and maintain strong EPS performance, it could attract more investors and drive the stock price higher.

Bear Case

Conversely, if the company fails to provide clear guidance on revenue or clinical trial results, it may lead to a sell-off, particularly given the recent volatility in its stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the current status of ongoing clinical trials and expected timelines for results?

The market will closely watch for updates on clinical trials, as these results can significantly impact the company's future prospects and stock price.

Will the company provide any revenue guidance or projections for the upcoming quarters?

Clear revenue guidance is essential for investor confidence, and any lack of clarity could lead to increased volatility in the stock.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential impact of Beam's clinical trial results, which could lead to significant upside if positive.

Supporting Evidence

The recent EPS surprise indicates that the company may be performing better than analysts expect.

Options pricing suggests that traders anticipate a larger move than historical averages, indicating potential for volatility.

The lack of revenue guidance may lead to overly cautious sentiment that doesn't reflect the company's actual progress.

Key Risk

If clinical trial results exceed expectations, it could significantly shift market sentiment and challenge current bearish views.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance hinges on the company's ability to communicate progress in its clinical trials and provide financial clarity.

Bull Confirmed If

Demonstrating a clear path to commercialization for its lead product candidates, with positive clinical trial results.

Bear Confirmed If

Failure to provide any revenue guidance or disappointing updates on clinical trials.

Pre-Earnings Positioning

Options Market

Implied Move

±10.82%

Historical Avg

±6.2%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±10.8% while BEAM has averaged ±6.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

75.7%

Calls (30K)P/C Ratio: 0.23Puts (40K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Beam beats expectations and raises guidance, history suggests a positive reaction, with an average 1-day move of +1.45%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but lack clarity, the stock may experience a muted reaction, reflecting investor caution.

Miss

If the company misses expectations, history suggests a potentially negative reaction, with an average 1-day move of -9.11%, indicating bearish sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the progress and results of clinical trials for lead product candidates.
2Any commentary on revenue projections or financial guidance for the upcoming quarters.
3Insights into the competitive landscape and how Beam's technology compares.
4Management's perspective on the regulatory environment and potential hurdles.
5Plans for future product development and pipeline expansion.